Diamedica (DMAC) Fundamental Analysis: Revenue, Earnings & Valuation

4.94 / 10

Netural

Fundamental rating is neutral at 4.9/10. Strengths include cash‑to‑market value, inventory turnover, low cost‑of‑sales ratio and PB‑ROE. Weak points are asset‑to‑market value, revenue‑to‑market value and gross profit margin, leading to a mixed financial profile.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score1/3

Weight13.54%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight3.50%

1M Return1.54%

Inventory turnover ratio

Value47.95

Score3/3

Weight17.96%

1M Return6.74%

Gross profit margin (%)

Value36.92

Score1/3

Weight-1.27%

1M Return-0.63%

PB-ROE

Value4.10

Score3/3

Weight28.17%

1M Return9.74%

Income tax / Total profit (%)

Value-0.07

Score2/3

Weight2.40%

1M Return1.04%

Fixed assets turnover ratio

Value7895.57

Score3/3

Weight2.31%

1M Return1.06%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight10.39%

1M Return4.32%

Asset-MV

Value-0.49

Score0/3

Weight7.05%

1M Return2.69%

Cash-MV

Value-0.09

Score2/3

Weight15.95%

1M Return5.94%

Is DMAC fundamentally strong?

DMAC scores 4.94/10 on fundamentals and holds a Fair valuation at present. Backed by its -67.68% ROE, 0.00% net margin, -10.56 P/E ratio, 6.17 P/B ratio, and -16.67% earnings growth, these metrics solidify its Netural investment rating.